South Korea Human Fibrinogen Market Size, Share, and COVID-19 Impact Analysis, By Type (Animal Fibrinogen, Human Fibrinogen Concentrate), By Application (Congenital Fibrinogen Deficiency, Surgical Procedures), and South Korea Human Fibrinogen Market Insights, Industry Trend, Forecasts to 2035

South Korea Human Fibrinogen Market Insights Forecasts to 2035

• The Market Size is Expected to Grow at a CAGR of around 9.5% from 2025 to 2035
• The South Korea Human Fibrinogen Market Size Is Expected to Hold a Significant Share By 2035

According to a research report published by Spherical Insights & Consulting, The South Korea Human Fibrinogen Market Size is anticipated to grow at a CAGR of 9.5% from 2025 to 2035. The market is driven by improvements in plasma fractionation and biotechnological procedures, as well as the rising incidence of bleeding disorders and other illnesses needing fibrinogen.

Market Overview

Products derived from plasma or those that are recombinant or processed are used in the human fibrinogen market to help patients with inherited or acquired deficiencies restore their fibrinogen levels and achieve haemostasis. It also contains related fibrinogen of animal origin that is utilized in research and as a few haemostatic adjuncts. Established plasma-fractionation capabilities, high surgical volumes, and rising awareness of guideline-based replacement therapy for acquired hypofibrinogenemia and congenital fibrinogen deficiency (CFD) during complex surgeries (liver, obstetric, and cardiac) all contribute to South Korea's demand. Because of their rapid reconstitution, viral safety profile, and standardized dosing, human fibrinogen concentrates (HFC) are becoming more and more popular over cryoprecipitate in perioperative and emergency care settings.

Report Coverage

This research report categorizes the market for the South Korea human fibrinogen market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea human fibrinogen market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea Human Fibrinogen market.

Driving Factors

The use of HFC is growing due to the complexity of surgical cases and the focus on quick, precise haemostasis. Compared to cryo, hospital procedures and viscoelastic testing support earlier fibrinogen correction. Supply reliability is improved by local distributor networks and plasma-fractionation expertise. The population being treated is further increased by ongoing clinician education regarding CFD and perioperative bleeding.

Restraining Factors

Rapid formulary expansion is constrained by pharmacoeconomic analysis and pricing/reimbursement controls. The availability of plasma and the strict requirements for quality and regulatory compliance affect supply.

Market Segmentation

The South Korea human fibrinogen market share is classified by type and application

• The human fibrinogen concentrate segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea human fibrinogen market is segmented by type into animal fibrinogen, human fibrinogen concentrates. Among these, the human fibrinogen concentrate segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. HFCs are recombinant or plasma-derived concentrates that are used to quickly and precisely treat fibrinogen deficiency. Their standardized potency, viral inactivation, ease of reconstitution, and predictable clinical results make them superior to cryoprecipitate.

• The surgical procedures segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea human fibrinogen market is segmented by application into congenital fibrinogen deficiency, surgical procedures. Among these, the surgical procedures segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Acquired fibrinogen deficiency during major surgeries, including heart, liver, trauma, and obstetrics, is covered by the largest application segment. For viscoelastic-guided transfusion protocols and perioperative bleeding control, hospitals are depending more and more on fibrinogen concentrates.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea human fibrinogen market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• CSL Behring
• LFB Group
• Kedrion Biopharma
• Grifols, S.A.
• Baxter International Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea human fibrinogen market based on the below-mentioned segments:

South Korea Human Fibrinogen Market, By Type

• Animal Fibrinogen
• Human Fibrinogen Concentrate

South Korea Human Fibrinogen Market, By Application

• Congenital Fibrinogen Deficiency
• Surgical Procedures